Bacterin International Holdings, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter of 2013
January 23, 2014 at 04:10 pm EST
Share
Bacterin International Holdings, Inc. provided preliminary unaudited revenue guidance for the fourth quarter of 2013. The company is expecting total net revenues for the fourth quarter of 2013 to be in the range of $8.15 million to $8.28 million, representing a sequential increase of approximately 4% over the third quarter 2013, and an increase of 1.5% when compared to $8.1 million for the fourth quarter 2012. The company is anticipating Biologics revenue to be in the range of $8.02 million to $8.07 million for the quarter, a 5.0% increase over the third quarter 2013, and 4.5% increase year-over-year.
Xtant Medical Holdings, Inc. is a global medical technology company. The Company is focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Its biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, and its line of 3Demin products, as well as other allografts. It offers a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor. Its key spinal implant product lines include Cervical Products, Thoracolumbar Products, Sacroiliac Joint Products, Interbody Products and Interlaminar Stabilization Products.
XTANT MEDICAL HOLDINGS, INC. 
